Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC (PER®), is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Kite, a Gilead Company.

Community Practice Connections™: Medical Crossfire: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond


Release Date: September 28, 2018
Expiration Date: September 28, 2019
Media: Internet - based

Activity Overview

The recent emergence and approval of chimeric antigen receptor (CAR) T cells have given even patients with highly chemorefractory hematologic malignancies additional treatment options. Community Practice Connections™: Medical Crossfire: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond features case-based discussion of the application of CAR T-cell therapy in patients with leukemia, lymphoma, and myeloma. Interactive clinical vignettes are followed by short video interviews with leading oncology experts and summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Kite, a Gilead Company.

 

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational program is directed toward medical oncologists, hematologists, nurses, and other oncology healthcare professionals interested in the latest advances in the use of CAR T-cell therapy for patients with lymphoid malignancies. Fellows, researchers, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with lymphoid malignancies are also invited to attend.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Recognize the unique mechanistic characteristics of CAR T-cell therapy for management of hematologic malignancies and the role of CAR T-cell therapy in the context of other emerging treatments
  • Understand the nuances of the manufacture of CAR T-cell therapy, including the quality standards of manufacturing, as well as the clinical relevance of production techniques and standards
  • Evaluate clinical trial data in the context of CAR T-cell therapy in the evolving treatment paradigms of hematologic malignancies
  • Define the potential treatment-related toxicities of CAR T-cell therapy and best practices for the monitoring, management, and mitigation of adverse events

Faculty, Staff, and Planners' Disclosures

Faculty

Andre H. Goy, MD, MS
Chairman, Executive Director, and
Lymphoma Division Chief, John Theurer Cancer Center
Chief Science Officer, Regional Cancer Care Associates
Hackensack, New Jersey
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University
Washington, DC

Disclosure: Grant/Research Support: Multi pharma relationships for clinical research through institutions Consultant: Celgene; Genentech; Pharmacyclics/J&J; Speaker’s Bureau: Acerta; Kite, a Gilead Company; Celgene; Cenentecy Pharmacyclics/J&J

Frederick L. Locke, MD
Vice Chair and Associate Member,
Department of Blood & Marrow Transplant and Cellular Immunotherapy
Co-Leader, Moffitt Immunology Research Program
Research Director and Medical Director, Immune Cell Therapy Program
Moffitt Cancer Center
Tampa, Florida

Disclosure: Grant/Research Support: Kite, a Gilead Company; Consultant: Cellular Biomedicine Group Inc

Sattva S. Neelapu, MD
Professor and Deputy Chair ad interim,
Department of Lymphoma and Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
 

Disclosure: Grant/Research Support: Kite, a Gilead Company; Merck; Bristol-Myers Squibb; Cellectis; Poseida; Consultant: Kite, a Gilead Company; Novartis; Merck; Celgene Shareholder: Precision Biosciences; Eureka Therapeutics

Cameron Turtle, MBBS, PhD
Associate Member, Clinical Research Division, Fred Hutchinson Cancer Center
Associate Professor, University of Washington School of Medicine
Seattle, Washington
 
 

Disclosure: Consultant: Aptevo; Juno Therapeutics/Celgene; Caribou Biosciences; Eureka Therapeutics; Precision Biosciences; Shareholder: Precision Biosciences; Eureka Therapeutics

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse Recap™

PER Pulse Recap (1 of 3)

CAR T-Cell Therapy for Patients With Relapsed Large B-Cell Lymphoma

Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond, which was held June 1, 2018, in Chicago, Illinois, updated physicians and other practitioners on the unique properties of chimeric antigen receptor (CAR)-modified T cells, as well as recent clinical data and approvals of CAR T cells for use in hematologic malignancies. This first of 3 PER Pulse™ Recaps from this program focuses on the approval of CAR T cells in patients with relapsed/refractory large B-cell lymphoma.

  • Axicabtagene ciloleucel received approval from the US Food and Drug Administration (FDA) in October 2017, based on the ZUMA-1 trial results, which enrolled patients with refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and transformed follicular lymphoma. In the patients with DLBCL, the overall response rate (ORR) was 82%, with 49% achieving a complete response (CR) at the time of primary analysis. In the overall trial, 40% of patients remained in CR even with a median follow-up of 15.4 months. In August 2018, European approval was granted to axicabtagene ciloleucel.
  • Tisagenlecleucel was approved by the US FDA in May 2018 for patients with relapsed/refractory DLBCL, based on the JULIET trial results. The best ORR was 53%, including a CR in 40% of patients; at 6 months, 30% remained in CR. The European Commission granted approval to tisagenlecleucel for DLBCL in August 2018.

For additional commentary about this topic and Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond, please visit gotoper.com.

<hr width="50%" "="">

PER Pulse Recap™

PER Pulse Recap (2 of 3)

Immune-Based Therapies for Patients With Acute Lymphoblastic Leukemia

Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond, which was held June 1, 2018, in Chicago, Illinois, updated physicians and other practitioners on the unique properties of chimeric antigen receptor (CAR)-modified T cells, as well as recent clinical data and approvals of CAR T cells for use in hematologic malignancies. This second of 3 PER Pulse™ Recaps from this program focuses on bispecific T-cell engagers and CAR T cells in patients with previously treated B-cell acute lymphoblastic leukemia (ALL).

  • Blinatumomab was approved by the US Food and Drug Administration (FDA) in July 2017 based on the phase III TOWER trial results. Patients with previously treated B-cell ALL were randomized to receive blinatumomab or standard chemotherapy. The median overall survival in the blinatumomab arm was superior (7.7 vs 4.0 months; P = .01); the rate of complete response (CR) was also higher with blinatumomab (34% vs 16%; P <.001)
  • Tisagenlecleucel was the first CAR T-cell therapy to be approved, with its initial indication for patients ≤25 years with B-cell precursor ALL in second relapse or later granted by the US FDA in August 2017. This approval was based on the ELIANA trial results, in which 81% of patients achieved a CR or CR with incomplete hematologic recovery. In August 2018, European approval for tisagenlecleucel in patients with ALL was granted.

For additional commentary about this topic and Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond, please visit gotoper.com.


The Emergence of CAR T Cells in Multiple Myeloma

Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond, which was held June 1, 2018, in Chicago, Illinois, updated physicians and other practitioners on the unique properties of chimeric antigen receptor (CAR)-modified T cells, as well as recent clinical data and approvals of CAR T cells for use in hematologic malignancies. This third of 3 PER Pulse™ Recaps from this program focuses on early-phase results with CAR T cells targeting the B-cell maturation antigen (BCMA) in patients with previously treated multiple myeloma (MM).

  • In a phase I trial, bb2121 was investigated in patients with MM and a median of 7 to 8 prior lines of therapy. An overall response rate (ORR) of 95.5% was reported, which included a complete response (CR) or stringent CR (sCR) in 50% of patients. In 16 patients who were evaluable for measurable residual disease (MRD), 100% achieved MRD negativity. Trials are ongoing with bb2121 to confirm these results, as well as to evaluate the activity of bb2121 in patients with high-risk MM who have early progression after 1 line of therapy.
  • IAnother BCMA-directed CAR T-cell therapy, LCAR-B38M, was investigated in patients who had approximately 3 to 4 prior lines of therapy. The ORR was 100%, with 63% of patients achieving an sCR. The successor to this agent, JNJ-68284528, is being further investigated in patients with MM and ≥3 prior lines of therapy.

    For additional commentary about this topic and Medical Crossfire®: The Advent of CAR T-Cell Therapy for Lymphoid Malignancies and Beyond, please visit gotoper.com.







Become a Member

Forgot Password?
Filter By